ERBB2 and gastric cancer: This drug was also studied in second line therapy of HER2 positive GC (previously treated with trastuzumab) within the GATSBY phase III trial [31]: unfortunately, TDM-1 therapy was not superior to standard taxanes (mOS 7.9 months versus 8.6 respectively, HR: 1.15, p = 0.86), although with lower incidence of adverse events.